PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Wednesday, August 31, 2022: Biosergen AB ("Biosergen" or the "Company") thereby publishes the interim report for the second quarter 2022. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q2 2022
2022 2021 2022 2021 2021
TSEK April-June April-June Jan-June Jan-June Jan-Dec
Consolidated group 1.409 2.001 2.726 2.001 11.570
revenue
Consolidated group -7.963 -9.493 -12.981 -17.798 -34.077
loss before
depreciation
Consolidated group -7.963 -9.493 -12.981 -8.305 -34.077
loss befor net
financials
Consolidated net -7.960 -9.504 -12.975 -17.809 -34.318
result
Consolidated earnings -0,28 -0,59 -0,46 -1,10 -1,22
per share (EPS)
- April 7, The first subject has been dosed in the phase 1 trial og BSG005
- May 13, Biosergen successfully completes first cohort of BSG005 phase 1 trial
- June 30, Biosergen successfully completes second cohort of BSG005 phase 1 trial
- August 26, Biosergen completes the third cohort of BSG005 phase 1 trial
- August 31, Biosergen receives a loan of SEK 7 million to finance continued development
The Financial report can be found on our website: https://biosergen.net/investors/filings